ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
暂无分享,去创建一个
Qiang Li | Joaquim Bellmunt | Nadeem Riaz | Huiyong Zhao | David B. Solit | Atanas Kamburov | Eliezer M. Van Allen | E. V. Van Allen | A. Kamburov | E. Plimack | G. Iyer | D. Bajorin | D. Solit | E. Jordan | J. Rosenberg | N. Riaz | A. D’Andrea | K. Mouw | J. Bellmunt | Philip H. Abbosh | David Liu | David Liu | J. Lazaro | Gopa Iyer | Jonathan E. Rosenberg | Jennifer Ma | Alan D. D'Andrea | Dean Bajorin | Elizabeth R. Plimack | Elizaveta Reznichenko | Alexis W. Damish | Zoë Frazier | Andrew Bell | Emmet J. Jordan | S. Paul Gao | Jennifer Ma | Jean-Bernard Lazaro | Kent W. Mouw | E. Reznichenko | A. Bell | Huiyong Zhao | S. Gao | Qiang Li | HuiYong Zhao | Zoë Frazier | A. Damish | E. V. Allen | David R. Liu | Philip H Abbosh | Alan D. D'Andrea | Qiang Li | Atanas Kamburov
[1] M. Berger,et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Plimack,et al. A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC. , 2018 .
[3] E. Schadt,et al. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. , 2017, European urology.
[4] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[5] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[6] A. Niemierko,et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.
[7] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[8] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[9] M. Berger,et al. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma , 2017, Clinical Cancer Research.
[10] L. Garraway,et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.
[11] M. O’Connor,et al. Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.
[12] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[13] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Mak,et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[16] Nicholas D James,et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. , 2014, European urology.
[17] Neville E. Sanjana,et al. Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.
[18] J. Hoeijmakers,et al. Understanding nucleotide excision repair and its roles in cancer and ageing , 2014, Nature Reviews Molecular Cell Biology.
[19] F. Couch,et al. Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.
[20] Mathew R Schnorenberg,et al. Monitoring Repair of UV-Induced 6-4-Photoproducts with a Purified DDB2 Protein Complex , 2014, PloS one.
[21] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[22] The Cancer Genome Atlas Research Network,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[23] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[24] J. Egly,et al. ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities , 2013, Proceedings of the National Academy of Sciences.
[25] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[26] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[27] S. Ramsey,et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.
[28] J. Egly,et al. Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients , 2009, The Journal of experimental medicine.
[29] H. Grossman,et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.
[30] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[31] R. Blasberg,et al. Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. , 2003, Neoplasia.
[32] R. Parshad,et al. XPD polymorphisms: effects on DNA repair proficiency. , 2000, Carcinogenesis.
[33] S. Lerner. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. , 1999, Lancet.
[34] T. Nishi,et al. Autocrine Growth of Transitional Cell Carcinoma of the Bladder Induced by Granulocyte-Colony Stimulating Factor 1 , 2006 .